Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial

被引：0
|
作者：
Fizazi, K. [1 ]
Mella, P. Gonzalez
Castellano, D.
Minatta, J. N.
Kalebasty, A. R.
Shaffer, D.
Limon, J. C. Vazquez
Lopez, H. M. Sanchez
Armstrong, A. J.
Horvath, L.
Bastos, D. A.
Amin, N. P.
Li, J.
Unsal-Kacmaz, K.
Retz, M.
Saad, F.
Petrylak, D. P.
Pachynski, R. K.
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
D O I：
10.1097/JU.0000000000003046
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：445 / 446
页数：2
相关论文
共 50 条
  • [11] Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study
    Nabhan, Chadi
    Patel, Anand
    Villines, Dana
    Tolzien, Kathy
    Kelby, Susan K.
    Lestingi, Timothy M.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (01) : 27 - 32
  • [12] Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
    Sharma, Padmanee
    Pachynski, Russell K.
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matthew D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit K.
    Ciprotti, Marika
    Simsek, Burcin
    Saci, Abdel
    Hu, Yanhua
    Han, G. Celine
    Fizazi, Karim
    CANCER CELL, 2020, 38 (04) : 489 - +
  • [13] Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial
    Wang, Yu
    Li, Jun
    Baden, Jonathan
    Gupta, Saurabh
    David, Justin M.
    CANCER RESEARCH, 2023, 83 (07)
  • [14] Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Bui, Cat N.
    O'Day, Ken
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 163 - U171
  • [15] Initial Results From a Phase 2 Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 8 - 10
  • [16] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Mark C. Markowski
    Mary-Ellen Taplin
    Rahul Aggarwal
    Laura A. Sena
    Hao Wang
    Hanfei Qi
    Aliya Lalji
    Victoria Sinibaldi
    Michael A. Carducci
    Channing J. Paller
    Catherine H. Marshall
    Mario A. Eisenberger
    David E. Sanin
    Srinivasan Yegnasubramanian
    Carolina Gomes-Alexandre
    Busra Ozbek
    Tracy Jones
    Angelo M. De Marzo
    Samuel R. Denmeade
    Emmanuel S. Antonarakis
    Nature Communications, 15
  • [17] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Markowski, Mark C.
    Taplin, Mary-Ellen
    Aggarwal, Rahul
    Sena, Laura A.
    Wang, Hao
    Qi, Hanfei
    Lalji, Aliya
    Sinibaldi, Victoria
    Carducci, Michael A.
    Paller, Channing J.
    Marshall, Catherine H.
    Eisenberger, Mario A.
    Sanin, David E.
    Yegnasubramanian, Srinivasan
    Gomes-Alexandre, Carolina
    Ozbek, Busra
    Jones, Tracy
    De Marzo, Angelo M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [18] Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
    Sharma, Padmanee
    Pachynski, Russell Kent
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matt D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit Kumar
    Ciprotti, Marika
    Duan, Tao
    Saci, Abdel
    Hu, Sarah
    Han, G. Celine
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [19] Enzalutamide: A Review of Its Use in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2015, 32 (03) : 243 - 249
  • [20] Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
    Sharma, Padmanee
    Krainer, Michael
    Saad, Fred
    Castellano, Daniel
    Bedke, Jens
    Kwiatkowski, Mariusz
    Patnaik, Akash
    Procopio, Giuseppe
    Wiechno, Pawel
    Kochuparambil, Samith Thomas
    Thomas, Christian
    Arija, Jose Angel Arranz
    McCune, Steven L.
    Hansen, Steinbjorn
    Daugaard, Gedske
    Amin, Neha P.
    Wang, Yumeng
    David, Justin M.
    Pachynski, Russell Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345